Corcept Therapeutics Incorporated Asset Resilience Ratio
Corcept Therapeutics Incorporated asset resilience ratio. Corcept Therapeutics Incorporated (CORT) has an Asset Resilience Ratio of 28.16% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CORT defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Corcept Therapeutics Incorporated (2002–2025)
Asset resilience ratio of Corcept Therapeutics Incorporated from 2002 to 2025. This chart shows how Corcept Therapeutics Incorporated's Asset Resilience Ratio has changed over time. Read how much debt does Corcept Therapeutics Incorporated carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Corcept Therapeutics Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Corcept Therapeutics Incorporated.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $229.45 Million | 28.16% |
| Total Liquid Assets | $229.45 Million | 28.16% |
Asset Resilience Insights
- Very High Liquidity: Corcept Therapeutics Incorporated maintains exceptional liquid asset reserves at 28.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Corcept Therapeutics Incorporated Industry Peers by Asset Resilience Ratio
Compare Corcept Therapeutics Incorporated's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Corcept Therapeutics Incorporated Asset Resilience Ratio by Year (2002–2025)
Corcept Therapeutics Incorporated asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Corcept Therapeutics Incorporated.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.08% | $251.66 Million | $836.65 Million | -0.34pp |
| 2024-12-31 | 30.42% | $255.67 Million | $840.55 Million | -7.02pp |
| 2023-12-31 | 37.44% | $232.67 Million | $621.52 Million | -25.18pp |
| 2022-12-31 | 62.62% | $365.34 Million | $583.43 Million | +28.19pp |
| 2021-12-31 | 34.43% | $145.92 Million | $423.76 Million | -29.32pp |
| 2020-12-31 | 63.75% | $364.51 Million | $571.73 Million | +4.41pp |
| 2019-12-31 | 59.35% | $244.69 Million | $412.31 Million | +6.37pp |
| 2018-12-31 | 52.98% | $165.13 Million | $311.69 Million | +26.82pp |
| 2017-12-31 | 26.16% | $57.68 Million | $220.54 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $68.75 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $51.94 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $34.63 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $63.08 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $99.17 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $39.83 Million | -- |
| 2008-12-31 | 18.17% | $3.59 Million | $19.77 Million | -15.27pp |
| 2007-12-31 | 33.44% | $5.93 Million | $17.74 Million | +27.88pp |
| 2006-12-31 | 5.55% | $550.00K | $9.90 Million | -78.22pp |
| 2005-12-31 | 83.78% | $25.26 Million | $30.16 Million | +17.90pp |
| 2004-12-31 | 65.88% | $31.47 Million | $47.77 Million | +53.11pp |
| 2003-12-31 | 12.77% | $1.50 Million | $11.78 Million | -1.65pp |
| 2002-12-31 | 14.42% | $3.14 Million | $21.80 Million | -- |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more